The Experts below are selected from a list of 21 Experts worldwide ranked by ideXlab platform

Duncan F Rogers - One of the best experts on this subject based on the ideXlab platform.

  • p137 why is erdosteine recommended as a treatment for acute exacerbations of chronic bronchitis a systematic review of clinical trials
    Thorax, 2016
    Co-Authors: C L Johnson, Duncan F Rogers
    Abstract:

    Background Exacerbations of chronic bronchitis or chronic obstructive pulmonary disease (COPD) are a significant health burden. A substantial component of these exacerbations in many patients is mucus-hypersecretion. Mucolytics, drugs that ‘thin’ mucus, have potential efficacy in these patients. Currently, erdosteine is the only mucolytic in the British National Formulary (BNF) indicated for “symptomatic treatment of acute exacerbations of chronic bronchitis”, while other BNF mucolytics (carbocisteine, Mecysteine and N-acetylcysteine) have had more general or non-respiratory indications, e.g. “reduction in sputum viscosity”. It is theorised that there is clinical evidence that erdosteine is useful in treatment of acute exacerbations of chronic bronchitis, unlike any of the other aforementioned mucolytics. Methods In this narrative systematic review, databases utilised included: Medline, Embase and PubMed. Studies for inclusion had to be Randomised Controlled Trials (RCTs) primarily investigating the effect of erdosteine in exacerbations of chronic bronchitis or COPD. For comparison, RCTs were also included if they investigated carbocisteine, Mecysteine and N-acetylcysteine’s effects in exacerbations. A secondary outcome was to investigate the use of these mucolytics in improving COPD signs and symptoms. Once selected, a two-stage publication elimination process was devised by the author to assess the quality of the trials. Results Very few trials of adequate quality assessed the efficacy of mucolytics in chronic bronchitis or COPD. Of the 5,560 search results, only 62 trials investigated the aforementioned mucolytics use in chronic bronchitis or COPD, 41 were RCTs. Of the 41 RCTs only 13 were found to be of adequate quality; erdosteine (1 RCT), carbocisteine (3 RCTs), Mecysteine (0 RCTs) and N-acetylcysteine (9 RCTs). There was no evidence that erdosteine is useful in treating exacerbations, and very limited, weak evidence for some efficacy in exacerbation prevention. In contrast, carbocisteine showed some strong evidence of efficacy in preventing exacerbations, especially in Asian populations. N-acetylcysteine trial results were variable, and evenly distributed between positive and no effects, with one study showing adverse effects. There were no trials of adequate quality investigating Mecysteine. Conclusion There is little evidence that erdosteine is useful in treating chronic bronchitis exacerbations, whereas, overall carbocisteine seems to be more efficacious in exacerbation prevention.

C L Johnson - One of the best experts on this subject based on the ideXlab platform.

  • p137 why is erdosteine recommended as a treatment for acute exacerbations of chronic bronchitis a systematic review of clinical trials
    Thorax, 2016
    Co-Authors: C L Johnson, Duncan F Rogers
    Abstract:

    Background Exacerbations of chronic bronchitis or chronic obstructive pulmonary disease (COPD) are a significant health burden. A substantial component of these exacerbations in many patients is mucus-hypersecretion. Mucolytics, drugs that ‘thin’ mucus, have potential efficacy in these patients. Currently, erdosteine is the only mucolytic in the British National Formulary (BNF) indicated for “symptomatic treatment of acute exacerbations of chronic bronchitis”, while other BNF mucolytics (carbocisteine, Mecysteine and N-acetylcysteine) have had more general or non-respiratory indications, e.g. “reduction in sputum viscosity”. It is theorised that there is clinical evidence that erdosteine is useful in treatment of acute exacerbations of chronic bronchitis, unlike any of the other aforementioned mucolytics. Methods In this narrative systematic review, databases utilised included: Medline, Embase and PubMed. Studies for inclusion had to be Randomised Controlled Trials (RCTs) primarily investigating the effect of erdosteine in exacerbations of chronic bronchitis or COPD. For comparison, RCTs were also included if they investigated carbocisteine, Mecysteine and N-acetylcysteine’s effects in exacerbations. A secondary outcome was to investigate the use of these mucolytics in improving COPD signs and symptoms. Once selected, a two-stage publication elimination process was devised by the author to assess the quality of the trials. Results Very few trials of adequate quality assessed the efficacy of mucolytics in chronic bronchitis or COPD. Of the 5,560 search results, only 62 trials investigated the aforementioned mucolytics use in chronic bronchitis or COPD, 41 were RCTs. Of the 41 RCTs only 13 were found to be of adequate quality; erdosteine (1 RCT), carbocisteine (3 RCTs), Mecysteine (0 RCTs) and N-acetylcysteine (9 RCTs). There was no evidence that erdosteine is useful in treating exacerbations, and very limited, weak evidence for some efficacy in exacerbation prevention. In contrast, carbocisteine showed some strong evidence of efficacy in preventing exacerbations, especially in Asian populations. N-acetylcysteine trial results were variable, and evenly distributed between positive and no effects, with one study showing adverse effects. There were no trials of adequate quality investigating Mecysteine. Conclusion There is little evidence that erdosteine is useful in treating chronic bronchitis exacerbations, whereas, overall carbocisteine seems to be more efficacious in exacerbation prevention.

Ma Ming-yang - One of the best experts on this subject based on the ideXlab platform.

  • Determination of Mecysteine hydrochloride by flow injection analysis with chemiluminescence detection
    Chinese Journal of Analysis Laboratory, 2008
    Co-Authors: Ma Ming-yang
    Abstract:

    It was found that a strong CL signal was detected when the mixture of lumino and KMnO4 was injected into Mecysteine hydrochloride solution in the alkaline medium.By unifying the flow injection technology a new method for fast determination of Mecysteine hydrochloride has been established.The chemiluminescence intensity was proportional to Mecysteine hydrochloride concentration over the range of 2.0×10-7～8.0×10-6 g/mL.The detection limit(3σ) was 9×10-8 g/mL and the relative standard deviation was 0.74% for 2.0×10-6 g/mL Mecysteine hydrochloride(n=11).This method has been successfully applied to the determination of Mecysteine hydrochloride in tablets.

W U Yangjiong - One of the best experts on this subject based on the ideXlab platform.

  • the serum homocysteine levels and dynamic changes in patients with different etiologic macrocytic anemia
    中国综合临床, 2009
    Co-Authors: Huiping Liu, Song Gao, Fanli Hua, W U Yangjiong
    Abstract:

    Objective To examine the serum homocysteine,folic acid and Vitamin B12 levels in macrocytic anemia patients and observe their dynamic changes following therapy. Methods Homocysteine,folic acid and Vita-min B12 were analyzed by electro-chemiluminescence immunoassay. Complete blood cell count was analyzed by opti-cal method and resistance method. Results The homocysteine is significantly higher in nutritional megaloblastic a-nemia[ (71.26±27.84)μmoL/L ] than in drug-induced megaloblastic anemia[(11.44±5.06)μmol/L],in myel-odysplastic syndrome[ (9.51±4.13)μmol/L] and in the normal control group[(8.74±5.42)μmoL/L] (P<0.01). After treated with low-dosage folic acid and Vitamin B12,the patients with megaloblastic anemia presented slow declining but eventually normal homocysteine levels,compared with those received high-dosages. Conclusion Homocysteine can be used for differential diagnosis of macrocytic anemia. The duration of remaining of abnormal ho-Mecysteine levels is related to the dosage of folic acid and Vitamin B12. Key words: Homocysteine; Folio acid; Vitamin B12; Macrocytic anemia

Huiping Liu - One of the best experts on this subject based on the ideXlab platform.

  • the serum homocysteine levels and dynamic changes in patients with different etiologic macrocytic anemia
    中国综合临床, 2009
    Co-Authors: Huiping Liu, Song Gao, Fanli Hua, W U Yangjiong
    Abstract:

    Objective To examine the serum homocysteine,folic acid and Vitamin B12 levels in macrocytic anemia patients and observe their dynamic changes following therapy. Methods Homocysteine,folic acid and Vita-min B12 were analyzed by electro-chemiluminescence immunoassay. Complete blood cell count was analyzed by opti-cal method and resistance method. Results The homocysteine is significantly higher in nutritional megaloblastic a-nemia[ (71.26±27.84)μmoL/L ] than in drug-induced megaloblastic anemia[(11.44±5.06)μmol/L],in myel-odysplastic syndrome[ (9.51±4.13)μmol/L] and in the normal control group[(8.74±5.42)μmoL/L] (P<0.01). After treated with low-dosage folic acid and Vitamin B12,the patients with megaloblastic anemia presented slow declining but eventually normal homocysteine levels,compared with those received high-dosages. Conclusion Homocysteine can be used for differential diagnosis of macrocytic anemia. The duration of remaining of abnormal ho-Mecysteine levels is related to the dosage of folic acid and Vitamin B12. Key words: Homocysteine; Folio acid; Vitamin B12; Macrocytic anemia